Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019

Peter D Burbelo, Francis X Riedo, Chihiro Morishima, Stephen Rawlings, Davey Smith, Sanchita Das, Jeffrey R Strich, Daniel S Chertow, Richard T Davey, Jeffrey I Cohen, Peter D Burbelo, Francis X Riedo, Chihiro Morishima, Stephen Rawlings, Davey Smith, Sanchita Das, Jeffrey R Strich, Daniel S Chertow, Richard T Davey, Jeffrey I Cohen

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related disease and death. Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune response.

Methods: Quantitative measurements of plasma or serum antibodies to the nucleocapsid and spike proteins were analyzed using luciferase immunoprecipitation system assays in 100 cross-sectional or longitudinal samples from patients with SARS-CoV-2 infection. A subset of samples was tested both with and without heat inactivation.

Results: At >14 days after symptom onset, antibodies against SARS-CoV-2 nucleocapsid protein showed 100% sensitivity and 100% specificity, whereas antibodies to spike protein were detected with 91% sensitivity and 100% specificity. Neither antibody levels nor the rate of seropositivity were significantly reduced by heat inactivation of samples. Analysis of daily samples from 6 patients with COVID-19 showed anti-nucleocapsid and spike protein antibodies appearing between days 8 and 14 after initial symptoms. Immunocompromised patients generally had a delayed antibody response to SARS-CoV-2, compared with immunocompetent patients.

Conclusions: Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody for detecting early infection. Analyzing heat-inactivated samples with a luciferase immunoprecipitation system assay is a safe and sensitive method for detecting SARS-CoV-2 antibodies.

Keywords: COVID-19; SARS-CoV-2; coronavirus; serology.

Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Figures

Figure 1.
Figure 1.
Detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid and spike protein in patients with coronavirus disease 2019 (COVID-19). Antibody levels against SARS-CoV-2 nucleocapsid and spike protein were determined in 32 pre-2018 blood donors, 10 patients with suspected COVID-19 (not confirmed with polymerase chain reaction [PCR]) from EvergreenHealth, Kirkland, Washington (EH) and patients PCR positive (PCR+) for COVID-19, including 3 from the University of California, San Diego (UCSD), 13 from the University of Washington (UW), 13 from EH, and 6 from the National Institutes of Health Clinical Center (NIH). Each symbol represents a sample from an individual patient or different time point from an individual patient. Antibody levels are plotted in light units (LU) on a log10 scale. Black circles represent plasma or serum samples obtained >14 days after symptom onset; orange circles, samples obtained ≤14 days after symptom onset; and dashed lines, cutoff levels for determining positive antibody titers, as described in Methods.
Figure 2.
Figure 2.
Longitudinal profile of antibodies against nucleocapsid and spike proteins in immunocompetent and immunocompromised patients with coronavirus disease 2019 (COVID-19) from the National Institutes of Health (NIH). Antibody levels were determined in daily blood samples from 6 patients with COVID-19. Three patients (NIH patients 1–3 [NIH-1, NIH-2, and NIH-3]) were immunocompetent (A) and 3 (NIH patients 4–6 [NIH-4, NIH-5, and NIH-6]) were immunocompromised (B). The levels of antibody to the nucleocapsid (black lines) and to spike (blue lines) proteins over time were plotted on the y-axis, using a log10 scale. Time 0 represents the day symptoms appeared; arrows, the time of diagnosis with polymerase chain reaction; dotted lines, cutoff values for determining seropositivity; and red X’s, the day after onset of symptoms that NIH patient 3 died.
Figure 3.
Figure 3.
Heat inactivation of plasma or serum samples has no significant impact on detection of nucleocapsid antibodies. A subset (n = 38) of plasma samples from patients with coronavirus disease 2019 (COVID-19) was analyzed, including samples from polymerase chain reaction–positive patients during very early infection (rs = 0.92; P < .001); only 1 sample showed a significant decrease with heating.

References

    1. Chan JF, Yuan S, Kok KH et al. . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395:514–23.
    1. Wu F, Zhao S, Yu B, et al. . A new coronavirus associated with human respiratory disease in China. Nature 2020; 579:265–9.
    1. Zhou P, Yang XL, Wang XG, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270–3.
    1. Chen L, Liu W, Zhang Q et al. . RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect 2020; 9:313–19.
    1. Chen N, Zhou M, Dong X et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–13.
    1. Huang C, Wang Y, Li X et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
    1. Zhu N, Zhang D, Wang W et al. . A Novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–33.
    1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17:181–92.
    1. Holshue ML, DeBolt C, Lindquist S et al. . First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382:929–36.
    1. Zou L, Ruan F, Huang M, et al. . SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382:1177–9.
    1. To KK, Tsang OT, Leung WS, et al. . Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020; 20:565–74.
    1. Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. doi: 10.1016/j.tmrv.2020.02.003.
    1. Chen W, Lan Y, Yuan X, et al. . Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect 2020; 9: 469–73.
    1. Leung DT, Tam FC, Ma CH, et al. . Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis 2004; 190:379–86.
    1. Zhu H, Hu S, Jona G, et al. . Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray. Proc Natl Acad Sci U S A 2006; 103:4011–6.
    1. Guo L, Ren L, Yang S et al. . Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020:ciaa310. doi: 10.1093/cid/ciaa310.
    1. Zhao J, Yuan Q, Wang H et al. . Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020:ciaa344. doi: 10.1093/cid/ciaa344.
    1. Wolfel R, Corman VM, Guggemos W et al. . Virological assessment of hospitalized patients with COVID-2019. Nature 2020. doi: 10.1038/s41586-020-2196-x.
    1. Li Z, Yi Y, Luo X et al. . Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020:10.1002/jmv.25727. doi: 10.1002/jmv.25727.
    1. Burbelo PD, Lebovitz EE, Notkins AL. Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl Res 2015; 165:325–35.
    1. Alagaili AN, Briese T, Mishra N, et al. . Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio 2014; 5:e00884–14.
    1. Zhou P, Fan H, Lan T, et al. . Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin. Nature 2018; 556:255–8.
    1. Yunoki M, Urayama T, Yamamoto I, Abe S, Ikuta K. Heat sensitivity of a SARS-associated coronavirus introduced into plasma products. Vox Sang 2004; 87:302–3.
    1. Leclercq I, Batéjat C, Burguière AM, Manuguerra JC. Heat inactivation of the Middle East respiratory syndrome coronavirus. Influenza Other Respir Viruses 2014; 8:585–6.
    1. Burbelo PD, Ching KH, Klimavicz CM, Iadarola MJ. Antibody profiling by luciferase immunoprecipitation systems (LIPS). J Vis Exp 2009:1549.
    1. Burbelo PD, Ferré EMN, Chaturvedi A, et al. . Profiling autoantibodies against salivary proteins in sicca conditions. J Dent Res 2019; 98:772–8.
    1. Wrapp D, Wang N, Corbett KS, et al. . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367:1260–3.
    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5: 536–44.
    1. Al-Muzairai IA, Mansour M, Almajed L, Alkanderi N, Alshatti N, Samhan M. Heat inactivation can differentiate between IgG and IgM antibodies in the pretransplant cross match. Transplant Proc 2008; 40:2198–9.
    1. Chen T, Wu D, Chen H et al. . Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091.
    1. Chen G, Wu D, Guo W et al. . Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130:2620–9.
    1. Guo T, Fan Y, Chen M et al. . Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020:e201017. doi: 10.1001/jamacardio.2020.1017.
    1. Wang W, Xu Y, Gao R et al. . Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323:1843–4.
    1. Darnell ME, Taylor DR. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion 2006; 46: 1770–7.
    1. Brenier-Pinchart MP, Fricker-Hidalgo H, Dard C, Pelloux H. Impact of heat-inactivation on anti-Toxoplasma IgM antibody levels. Clin Chem Lab Med 2017; 55: e291–3.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera